Scribe Therapeutics Inc.
SCTX
IPO
$29.41
-$1.93-6.16%
NASDAQ
| 06/30/2026 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Net Income | 62.66% | -189.14% | |||
| Total Depreciation and Amortization | 1.55% | -3.02% | |||
| Total Amortization of Deferred Charges | -- | -100.00% | |||
| Total Other Non-Cash Items | -82.32% | 1,005.13% | |||
| Change in Net Operating Assets | -158.58% | 110.69% | |||
| Cash from Operations | 29.36% | 51.32% | |||
| Capital Expenditure | 41.18% | 10.59% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 40.86% | -85.52% | |||
| Cash from Investing | 40.95% | -87.28% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | 55.91% | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -201.98% | 200.00% | |||
| Cash from Financing | -235.04% | 2,750.00% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 100.46% | -153.69% | |||